Transtympanic Micropressure Treatment for Ménière’s Disease

Policy MP-032

Origination Date: 11/15/18
Reviewed/Revised Date: 11/15/18
Next Review Date: 11/15/19
Current Effective Date: 11/15/18

Disclaimer:
1. Policies are subject to change without notice.
2. Policies outline coverage determinations for U of U Health Plans Commercial, and Healthy U (Medicaid) plans. Refer to the “Policy” section for more information.

Description:
Ménière’s disease is an idiopathic disorder of the inner ear characterized by episodes of vertigo, fluctuating hearing loss, tinnitus, and ear pressure. Vertigo can be described as a dizzy or spinning sensation. Individuals may experience vertigo as an illusion of motion, vague dizziness, imbalance, disorientation, transient spinning or a sense of swaying or tilting. The vertigo attacks are often unpredictable and incapacitating and may prevent activities of daily living. Therapy addresses symptoms, not the underlying pathophysiology. A low sodium diet and diuretics to reduce fluid accumulation (i.e. hydrops) and pharmacologic therapy to reduce vestibular symptoms may be used as conservative therapy. No therapy is available to restore hearing loss. Although the pathophysiology of Ménière’s disease is not precisely known, it is thought to be related to a disturbance in the pressure/volume relationship of the endolymph within the inner ear.

There has been interest in developing a more physiologic approach to treatment by applying local transtympanic pressure to restore the underlying fluid homeostasis. The symptoms of Ménière’s disease seems to improve with fluctuations in ambient pressure, and patients with acute vertigo have been successfully treated in hypobaric chambers. It is hypothesized that the application of low-frequency, low amplitude pressure pulse to the middle ear functions to evacuate endolymphatic fluids from the inner ear, thus relieving vertigo. Transtympanic micropressure treatment for Ménière’s disease involves use of a handheld air low-pressure generator (Meniett device) that delivers intermittent complex pressure pulses.
Policy Statement and Criteria

1. Commercial Plans

U of U Health Plans does NOT cover the Meniett low-pressure pulse generator for the treatment of Ménière’s disease, nausea/vomiting, or tinnitus as it is considered experimental/investigational because its effectiveness has not been established.

2. Medicaid Plans

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the U of U Health Plans Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website at http://health.utah.gov/medicaid/manuals/directory.php or the Utah Medicaid code Look-Up tool.

Clinical Rationale

The Equilibrium Committee of the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) revised their recommendation for the use of micropressure therapy (e.g., the Meniett device) in 2016. They found some evidence to support its use in certain cases of Ménière’s disease and as a second level therapy when medical treatment has failed or the device represents a largely non-surgical therapy. No specific criteria for treatment are listed. Furthermore, this AAO-HNS position does not appear to be supported by a traditional technology assessment of the device/therapy.

A 2015 systematic review (Syed et al) evaluated the effectiveness of the Meniett device in reducing the frequency and severity of vertigo in Ménière’s disease. Four randomized controlled trials (RCTs) compared the effectiveness of the Meniett device in 123 patients versus a placebo device in 114 patients with Ménière’s disease, over a follow-up period of 2 weeks to 4 months. The outcome data were dichotomous for all the included trials. An overall 61% of reduction in the frequency of vertigo in both groups were reported. This reduction was not significantly different in any study or meta-analysis between the 2 groups (mean difference in vertigo free days between Meniett and placebo device of 0.77 days over a 1-month period [95% confidence intervals (CI): -0.82 to 1.83] p = 0.45). No substantial data reported reduction in the severity of vertigo with the Meniett device compared to the placebo device. No evidence was found to support any efficacy for use of the Meniett device in patients with Ménière’s disease.

A 2015 Cochrane review (van Sonsbeek et al) evaluated the effects of positive pressure therapy for the symptoms of patients with Ménière’s disease. The review included 5 double blind RTCs (total N=265 patients) comparing positive pressure therapy (using the Meniett or a similar device) with placebo in patients with Ménière’s. Overall, the risk of bias varied between the 5 trials; 3 trials were considered low risk, 1 was at unclear risk, and 1 was at high risk. In spite of it not being possible to pool data due to heterogeneity in the measurement of outcomes, results on the primary outcome was control of vertigo and the results on secondary outcomes were loss or gain of hearing, severity of tinnitus, perception of aural fullness, functional level, complications or adverse effects, and sick days. However, most trials showed no significant difference in vertigo between positive pressure therapy and placebo. No complications or adverse effects were reported by any study. The positive pressure therapy device itself is minimally invasive. However, in order to use it, a tympanostomy tube needs to be inserted, with the associated risks. The review concluded that the evidence did not support the efficacy of positive
pressure therapy for the treatment of Meniere disease and 2 of the studies shown evidence that hearing impairments were worse with this treatment.

Subsequent to the 2015 Cochrane review, in 2017 an industry-sponsored, multicenter, double-blind RCT (Russo et al) evaluated the effectiveness of the portable Meniett device (a low-pressure pulse generator) protocol for total of 129 adult patients with Ménière's disease that included 3 phases; the first phase patients received placement of a transtympanic tube whose vertigo was not controlled by medical treatment and were withdrawn from the trial if symptoms improved; the second phase had a total of 97 patients that passed the first phase and included 6 weeks of treatment with the Meniett or a placebo device (49 received the Meniett device and 48 the placebo device, respectively); and the third phase included removal of the device and a 6 week follow-up period. The number of vertigo episodes during the baseline period did not differ significantly between groups (p=0.07). Again the study concluded there was no significant difference between the Meniett and placebo device groups, there was still an improvement of symptoms demonstrated in all patients, which could be explained by an effect of the transtympanic tube.

An UpToDate review on “Ménière's disease” (Moskowitz, 2018) states that “long-term efficacy of overpressure in the control of vertigo is uncertain and hearing conservation should not be expected in all patients choosing this therapy." Additional tympanostomy tube maintenance is required and the device is expensive. Further additional independent, well-designed studies with larger populations along with comparative effectiveness and long-term patient compliance are needed before definitive conclusions can be made regarding the full benefit of this therapy in the general clinical setting.

Applicable Coding

CPT Codes
No applicable codes

HCPCS Codes

E2120  Pulse generator system for tympanic treatment of inner ear endolymphatic fluid

References:

3. Moskowitz, HS, Dinces EA. Meniere disease. UpToDate [online serial]. Waltham, MA: UpToDate; last update April 2018; reviewed September 2018.

Disclaimer:
This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member’s individual benefit plan that is in effect at the time services are rendered.
The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

U of U Health Plans makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. U of U Health Plans updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to health care providers or U of U Health Plans members.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from U of U Health Plans.

"University of Utah Health Plans" and its accompanying logo, and its accompanying marks are protected and registered trademarks of the provider of this Service and or University of Utah Health. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association